Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases, announced its participation in the BTIG Virtual Biotechnology Conference 2024. Russell Trenary, President and CEO, will engage in a fireside chat on Monday, August 5th at 8:00 AM ET.
The company's management team will also be available for one-on-one virtual meetings with qualified investors attending the conference. Interested parties are advised to contact their BTIG representative to schedule meetings with Outlook Therapeutics during the event.
Outlook Therapeutics (Nasdaq: OTLK), un'azienda biofarmaceutica che sviluppa ONS-5010/LYTENAVA™ (bevacizumab-vikg) per le malattie retiniche, ha annunciato la sua partecipazione alla BTIG Virtual Biotechnology Conference 2024. Russell Trenary, Presidente e CEO, prenderà parte a una conversazione informale lunedì 5 agosto alle 8:00 AM ET.
Il team di gestione dell'azienda sarà disponibile anche per incontri virtuali individuali con investitori qualificati che parteciperanno alla conferenza. Le parti interessate sono invitate a contattare il proprio rappresentante BTIG per programmare incontri con Outlook Therapeutics durante l'evento.
Outlook Therapeutics (Nasdaq: OTLK), una compañía biofarmacéutica que desarrolla ONS-5010/LYTENAVA™ (bevacizumab-vikg) para enfermedades de la retina, anunció su participación en la BTIG Virtual Biotechnology Conference 2024. Russell Trenary, Presidente y CEO, participará en una charla informal el lunes 5 de agosto a las 8:00 AM ET.
El equipo de gestión de la empresa también estará disponible para reuniones virtuales individuales con inversionistas calificados que asistan a la conferencia. Se aconseja a los interesados que contacten a su representante de BTIG para programar reuniones con Outlook Therapeutics durante el evento.
Outlook Therapeutics (Nasdaq: OTLK)는 망막 질환을 위한 ONS-5010/LYTENAVA™ (bevacizumab-vikg)를 개발하는 생물 제약 회사로, BTIG 가상 생명공학 컨퍼런스 2024에 참여할 것이라고 발표했습니다. Russell Trenary 사장 겸 CEO는 8월 5일 월요일 오전 8시 ET에 포럼 대화에 참석할 예정입니다.
Outlook Therapeutics (Nasdaq: OTLK), une société bio-pharmaceutique développant ONS-5010/LYTENAVA™ (bevacizumab-vikg) pour les maladies de la rétine, a annoncé sa participation à la BTIG Virtual Biotechnology Conference 2024. Russell Trenary, Président et CEO, participera à une discussion informelle le lundi 5 août à 8h00 ET.
L'équipe de direction de l'entreprise sera également disponible pour des réunions virtuelles individuelles avec des investisseurs qualifiés assistant à la conférence. Les parties intéressées sont invitées à contacter leur représentant BTIG pour planifier des réunions avec Outlook Therapeutics pendant l'événement.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, das ONS-5010/LYTENAVA™ (bevacizumab-vikg) für Netzhauterkrankungen entwickelt, gab seine Teilnahme an der BTIG Virtual Biotechnology Conference 2024 bekannt. Russell Trenary, Präsident und CEO, wird am Montag, den 5. August um 8:00 Uhr ET an einem informellen Gespräch teilnehmen.
Das Management-Team des Unternehmens wird auch für einzelne virtuelle Meetings mit qualifizierten Investoren, die an der Konferenz teilnehmen, zur Verfügung stehen. Interessierte Parteien wird geraten, ihren BTIG-Vertreter zu kontaktieren, um Meetings mit Outlook Therapeutics während der Veranstaltung zu planen.
- None.
- None.
Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET
ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2024 on Monday, August 5, 2024 at 8:00 AM ET.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. If you are interested in scheduling a meeting with Outlook Therapeutics during the conference, please reach out to your BTIG representative.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and United Kingdom Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD in the first calendar quarter of 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA application to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the BTIG Virtual Biotechnology Conference 2024?
Who will be representing Outlook Therapeutics (OTLK) at the BTIG Virtual Biotechnology Conference?
What type of presentation will Outlook Therapeutics (OTLK) be giving at the BTIG conference?
Can investors meet with Outlook Therapeutics (OTLK) management during the BTIG conference?
What is the main product Outlook Therapeutics (OTLK) is developing?
